Home / Healthcare / Optical Pr

Optical Preclinical Imaging Market By Modality (Bioluminescence/Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems, Optical + X-Ray/Optical + CT) By Reagent (Bioluminescent Imaging Reagents, Fluorescent Imaging Reagents) By Application (Research & Development, Drug Discovery) - Growth, Future Prospects, And Competitive Analysis, 2016 -2028

About this report

The global Optical Preclinical Imaging Market report explores the critical analysis of the Optical Preclinical Imaging industry using key parameters. The report consists of investment strategies, the need for investments in the Optical Preclinical Imaging industry, and the multiple benefits for the investors. Importantly, this report sets out major changes in the global technical regulations for the Optical Preclinical Imaging industry and how economic and non-economic barriers are helping the Optical Preclinical Imaging market grow. Moreover, the report analyzes the global, regional, and country-level historic and forecasted market size. The report also provides a comprehensive analysis of key investment propositions, demand and supply gap, competitors positioning, STAR analysis, SRC analysis, and Tornado analysis. Key technological developments and other analyses such as porter's five forces analysis, PESTEL analysis, value chain analysis, etc.


Key Highlights of the report

How are the major segments performing in the Optical Preclinical Imaging Market?

In 2021, the bioluminescence/fluorescence imaging systems segment will be the leading segment by modality due to the rapid commercialization of these systems and their technologically advanced integration.

In 2021, the research institutes segment was the major segment by end-user. In-vivo imaging systems are being adopted by more clinical research institutes and pharmaceutical companies in preclinical research, which is further anticipated to fuel the growth of this market. Moreover, alternative approaches for clinical research, including in-vitro testing, micro-dosing, computer-based models, virtual drug testing, and creating computerized databases for testing, are being adopted more and more frequently by research institutes.

Which region dominated the Optical Preclinical Imaging Market?

The optical preclinical imaging market was dominated by North America in 2021, with a revenue share of about 29%. The presence of qualified specialists, a sizable number of preclinical projects, and greater acceptance rates of technologically advanced equipment in the region are some key market factors in North America. Additionally, regional clinical research and development programs are being encouraged by government initiatives. One such government program promoting R&D efforts in the nation is the Canadian R&D tax credit scheme. The market is benefiting from government support through money and tax breaks.

What is the competitive environment of the Optical Preclinical Imaging Market?

The optical preclinical imaging market is quite competitive and fragmented. Market participants actively put strategic initiatives into action, such as portfolio diversification, product enhancements, geographical expansions, and mergers and acquisitions. These firms also frequently work with academic institutions, universities, and other end users to influence preclinical research in the market. For instance, in October 2020, prestigious institutions placed orders of up to $10 million with MR Solutions for their preclinical equipment. The most popular products among market participants included 9.4T and 7T cryogen-free DRY magnets, PET/CTs, and PET/MRs.

Executive Summary

What are the technological developments being developed in the Optical Preclinical Imaging Market?

Research in important fields like oncology, cardiology, infection, and neurology will continue to expand as a result of the combination of high-resolution modalities like micro-CT or micro-MRI with highly sensitive methods that provide functional information like micro-PET or micro-SPECT, helping to not only understand the underlying mechanisms of disease but also providing effective and special tools for assessing novel chemical entities and candidate drugs. Because of their increased benefits, pharmaceutical corporations, contract research organizations, and academic institutions rapidly use small-animal imaging techniques.

Which are the key investments by the players in the Optical Preclinical Imaging Market?

Key players make various investments throughout the market through acquisitions and new product launches to expand their business revenue mix. For instance, the seventh generation of preclinical imagers was introduced by MILABS during the 2021 World Molecular Imaging Conference in October. MILabs is elevating the value of its ecosystem of preclinical goods under the new ownership of the Rigaku Group (Tokyo, Japan). MOLECUBES, NV, a dynamic innovator in benchtop preclinical nuclear molecular imaging (NMI) systems, was acquired by The Bruker Corporation in November 2021. The position of Bruker as a premier NMI solutions provider for preclinical and translational imaging research is strengthened by this purchase.

Some of the major players in the market are Bruker Corporation, MR Solutions, PerkinElmer, Inc., TriFoil Imaging, FUJIFILM Holdings America Corporation, Mediso Ltd., Miltenyi Biotec, Vieworks Co., Ltd., UVP, and MILabs B.V.

What are the Major Driving Factors for the Optical Preclinical Imaging Market?

The market is expanding primarily due to increased investments and financing for R&D, as well as the rapid pace of technological improvements that have led to the creation of hybrid imaging systems. Preclinical research is changing how modern medicine is practiced and addresses health issues. Preclinical imaging methods fully adhere to 3R (Replacement, Reduction, and Refinement) policies by reducing biological variability, acquiring a remarkable amount of distinctive information in various forms, and drastically reducing the number of animals needed for a given study. As there are more Clinical Research Organizations (CROs) and pharmaceutical companies, in-vivo imaging systems are being used more frequently in preclinical research, which is anticipated to boost the expansion of this market.

What are the Major Risks for the Optical Preclinical Imaging Market?

The main obstacles to the market's expansion are the limitations on animal testing imposed by laws enforced by groups that defend animal rights. Alternative techniques are quickly gaining acceptance, including in-vitro tests, microdosing, computer-based models, virtual drug testing, and the development of computerized databases for testing. High installation and operating costs are another significant industry constraint.

Which is the key modality in the Optical Preclinical Imaging Market?

The bioluminescence/fluorescence imaging systems dominated the Optical Preclinical Imaging market in 2021. Molecular events and biological processes can be studied in vivo without intervention using the optical imaging technique known as bioluminescence. This imaging technique is non-invasive and permits real-time biological process analysis. Thanks to this approach, researchers have analyzed disease development, protein-protein interactions, therapeutic success, and many other topics. Comparing bioluminescence to traditional fluorescence readouts, there are several distinctive benefits. The main benefit of using bioluminescent signals is that they can be used for long-term imaging applications with no risk of phototoxicity or artifact since they can be recognized over very little to no background noise. High sensitivity, high specificity, no phototoxicity (damage caused by high and low wavelength light), and non-invasiveness are all benefits of bioluminescence imaging. High signal-to-noise ratio (low background), simultaneous imaging of multiple organisms (instrument dependent), high sensitivity, and high specificity are other benefits. 

How is the Optical Preclinical Imaging Market performing in regions?

North America dominated the optical preclinical imaging market with a revenue share of almost 29% in 2021. Some of the important market aspects in North America are the availability of qualified specialists, the sizeable number of preclinical projects, and higher adoption rates of technologically advanced equipment in the region. Government initiatives are also supporting regional clinical research and development programs. The Canadian R&D tax credit program is one of the government initiatives supporting national R&D activities. Government assistance in the form of funds and tax breaks benefits the market. Due to its developed infrastructure and significant governmental and private firms, the United States is also recognized as the market leader. The preclinical imaging market is expanding more quickly in the United States thanks to increased funding for research and development and well-established research infrastructure. Additionally, the rising usage of in-vivo imaging systems in Preclinical research due to the rise in clinical research organizations (CROs) and pharmaceutical corporations is further fueling the growth of this market. 

The market is expanding profitably throughout the Asia Pacific. Preclinical research studies are attracted to the region due to inexpensive research costs, lax regulatory requirements, and increased government financing for the growth of the research and development sector in different countries. As a result, growing nations like China and India are experiencing rapid growth in the Clinical Research Outsourcing (CRO) sector. 

What is the regulatory landscape for the Optical Preclinical Imaging Market?

The market for optical preclinical imaging is anticipated to have difficulties due to the strict regulatory environment governing preclinical research. The technical and procedural rules are developed about autonomous systems and the demand for proof based on clinical trials. Additionally, governments have implemented strict restrictions on animal testing.

What is the Market Size of Optical Preclinical Imaging regarding value?

The global Optical Preclinical Imaging Market is anticipated to grow at a substantial CAGR of 5.0% in the upcoming years. The global Optical Preclinical Imaging industry was estimated to be worth USD 519.4 million in 2021 and was expected to be worth USD 696.1 million by 2028.

What are the major players planning for the future of the Optical Preclinical Imaging Market?

Businesses are introducing new items to diversify their product line. For instance, according to Bruker, the market-leading Ultima family of multiphoton microscopes for deep tissue fluorescence imaging will introduce the Ultima Investigator Plus in March 2022. With an enlarged close-coupled collecting path, an expanded field of view, and optimized optics for two- and three-photon imaging, Investigator Plus improves scientists' ability to image deeply and see more inside challenging specimens. Additionally, businesses are developing new items to diversify their product offering. For instance, Bruker announced that the Ultima Investigator Plus, the most recent flexible platform addition to the leading-edge Ultima line of multiphoton microscopes for deep tissue fluorescence imaging, would be released in March 2022.

Segmentation of Global Optical Preclinical Imaging Market-

Global Optical Preclinical Imaging Market – By Modality

  • Bioluminescence/Fluorescence Imaging Systems
  • Standalone Fluorescence Imaging Systems
  • Optical + X-Ray/Optical + CT

 Global Proximal Humerous Implants Market – By Reagent

  • Bioluminescent Imaging Reagents
  • Fluorescent Imaging Reagents

Global Optical Preclinical Imaging Market – By Application

  • Research & Development
  • Drug Discovery

Global Optical Preclinical Imaging Market – By End-user

  • Pharmaceutical Companies
  • Biotech Companies
  • Research Institutes

Global Optical Preclinical Imaging Market – By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • South-east Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East and Africa

Frequently asked questions about the global optical preclinical imaging market-

The delay of non-essential medical services, the scarcity of medical facilities and treatment centers, trade restrictions, the suspension of various activities, the drop in demand, and the interruptions to the supply chain brought on by the COVID-19 outbreak all had a significant impact on healthcare.

North America accounted for the highest share in the global optical preclinical imaging market.

Increase in demand for non-invasive imaging techniques and increasing government funding for research & development activities are the major factors driving the market's growth.

Bioluminescence/Fluorescence Imaging Systems had a major share in 2021 with the market revenue share. Besides, it is also projected to witness the fastest growth.

The Research Institutes had a major share in the global market in 2021.

Optical Preclinical Imaging Market Scope

Report Attribute Details
Market Value in 2021 USD 519.4 million
Market Value in 2028 USD 696.1 million
CAGR 5.0%
Benchmarking Year 2021
Past data 2016 – 2021
Forecast period 2022 – 2028
Choose License Type
Trusted By
Published Date:  Oct 2022
Category:  Healthcare
Report ID:   60715
Report Format:   PDF
Pages:   120
Rating:    4.6 (50)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support